Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Google-Backed Calico Project Will Investigate Anti-Aging Technologies

This article was originally published in The Pink Sheet Daily

Executive Summary

The Internet search and advertising giant has tapped Genentech and Apple chairman Art Levinson to lead a new initiative that will explore aging and related diseases. Google will invest an undisclosed amount to launch the latest Silicon Valley-funded effort to extend human longevity.

You may also be interested in...



Start-Up Quarterly Statistics, Q3 2014

Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.

Craig Venter Wants To Extend Your Life (And Own Your Data)

The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.

Venter Targets Life Extension With New Genomic Research Company

The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel